Healthcare Industry News: EpiCeram
News Release - October 14, 2008
Dr. Reddy's Wholly-Owned Subsidiary Promius Pharma Launches EPICERAM(R) Skin Barrier Emulsion
EpiCeram(R) Is a New Approach to Treatment of Atopic DermatitisLaunch of First Dermatology Prescription Product in the U.S.
HYDERABAD, India--(HSMN NewsFeed)--Promius Pharma, LLC, a wholly owned subsidiary of Dr. Reddy’s Laboratories (NYSE:RDY ) announced the launch of its first product, EpiCeram® Skin Barrier Emulsion. EpiCeram® Emulsion is a novel prescription therapy for the treatment of atopic dermatitis, a skin disease that affects more than 15 million patients in the United States.
Promius Pharma will launch EpiCeram Emulsion this week at the 27th Annual Fall Clinical Dermatology Conference in Las Vegas, NV, which will be attended by over 400 dermatologists and healthcare providers.
Commenting on the launch of its first dermatology prescription product in the US market, Jeffrey Wasserstein, Executive Vice President of Promius Pharma said, “This product was developed to specifically address the defective skin barrier of atopic patients to safely and effectively control the signs and symptoms of atopic dermatitis. EpiCeram® Emulsion is our first commercialized product and it aligns with our core strategy of striving to meet unmet medical needs. EpiCeram® has the potential to change how doctors treat mild to moderate atopic dermatitis.”
Notes to the editor:
- The addressable Atopic Dermatitis market size in the US is estimated at $400 million.
- EpiCeram® Emulsion is based on scientific advances in the understanding of the skin barrier and its role in the pathogenesis of atopic dermatitis.
- EpiCeram® Emulsion provides an optimal 3:1:1 ratio of ceramides, free fatty acids and cholesterol to help repair the damaged skin barrier in-order to relieve the signs and symptoms of atopic dermatitis.
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddy’s
Established in 1984, Dr. Reddy's Laboratories (NYSE:RDY ) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer. www.drreddys.com
About Promius Pharma LLC
Promius Pharma is a wholly owned, branded specialty company, of Dr. Reddy’s Laboratories Inc. It is located in Bridgewater, NJ. Promius Pharma is a focused, leading-edge company that develops and markets innovative solutions for challenging dermatological conditions with an eye to the future to redefine therapeutic options for physicians and patients.
Please see EpiCeram Patient Information sheet for full prescribing information and contraindications. For more information visit www.promiuspharma.com or www.EpiCeram.com.
Source: Dr. Reddy's Laboratories
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
